Back
Header image

Transforming global genetic data into medical decisions

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Latest Scientific News

Confirmation of ACER3-related recessive neurodegeneration

Learn more about our recent findings in confirmation of ACER3-related recessive…

Article with topic Metabolism, WES
Read more

Association of hydrocephalus and renal dysplasia

Read more about our recent findings in association of hydrocephalus and renal dysplasia…

Article with topic Neurology
Read more

Novel clinical and genetic insights into dysfunction of the ASC-1 complex

The transcriptional coactivator ASC-1 complex is composed of four subunits ASC-1 (TRIP4),…

Article with topic Neurology
Read more

HTRA2 Defect: a recognizable inborn error of metabolism

Neonatal-onset movement disorders, especially in combination with seizures, are rare and…

Article with topic Neurology
Read more

Customer Feedback

Give feedback

Newsletter subscription

CENTOGENE Corporate and Business Unit Update 2018

2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases...

 Read more
Centogene,

CENTOGENE earns Accreditation to ISO 15189:2012 from CAP

NORTHFIELD, IL. — The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded...

 Read more
Centogene,

Updates to CentoMD®, World’s Largest Genetic Mutation Database of Rare Diseases

Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases

 Read more
Centogene,

CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation...

 Read more
Centogene,

CENTOGENE and EVOTEC sign global strategic partnership

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

 Read more
Centogene,

Entrepreneur of the year 2018 in Wismar honored

We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We are...

 Read more
Centogene,

Partnership with the Universities of Greifswald and Rostock

CENTOGENE announced today a partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development of...

 Read more
Centogene,

CENTOGENE to open first U.S. Laboratory in Cambridge, MA

CENTOGENE announced today the opening of its first U.S. based rare disease laboratory in Cambridge, Massachusetts.  The new facility, opening on August 1, 2018,...

 Read more
Centogene,

Mini-symposium at CENTOGENE: „Patient-individualized vaccination in cancer“

CENTOGENE, driving the diagnostic workflows and individualized therapeutic decisions not only in rare diseases but also in oncological setups is proud to host...

 Read more
Centogene,